ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

mocertatug rezetecan

Also written as “Mocertatug rezetecan”, “HS-20089” and “Mocertatug rezetecan (Mo-Rez)”.

In GlaxoSmithKline’s pipeline, ADC targeting B7-H4. Its studies are mostly in Ovarian Neoplasms · Endometrial Neoplasms · Neoplasms, led by 2 companies.

Drug pageMocertatug rezetecan: every studyAll 12 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Dec 12, 202511 company-led studies, 11 open or runningLicense: Hansoh → GSK, Oct 2023Next primary completion: Mar 7, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GlaxoSmithKline66 open or runningphase 3since Dec 12, 2025May 21, 2024Sep 22, 2027phase 1 · NCT06431594
Hansoh Pharmaceutical Groupits history only55 open or runningphase 3since Feb 25, 2025Oct 29, 2021Mar 7, 2027phase 3 · NCT06855069
  • Named in GlaxoSmithKline’s own pipeline as mocertatug rezetecan GSK5733584, phase 3, as of Sep 30, 2026 (source).
  • Named in Hansoh Pharmaceutical Group’s own pipeline as HS-20089 (B7-H4 ADC), phase 3, as of Aug 26, 2026 (source).

How these companies relate

From the companies’ own releases and filings, each linked; the registry does not say.

  • LicenseGSK licensed it from Hansoh, for everywhere outside mainland China, Hong Kong, Macau and Taiwan.Announced Oct 20, 2023 · Source: GSK, Oct 20, 2023

History and studies of GlaxoSmithKline only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). A diamond marks a license, acquisition or co-development, from the companies’ own releases and filings. An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Oct 20, 2023GSK licensed it from HansohLicenseEverywhere outside mainland China, Hong Kong, Macau and Taiwan · announced · GSK
  2. May 21, 2024First study: phase 1 study in NeoplasmsFirst studyNCT06431594 · 675 planned · United States, Argentina, Australia and more
  3. Jul 10, 2025Named mocertatug rezetecanINNProposed as its International Nonproprietary Name in WHO's List 133 · before, HS-20089
  4. Dec 12, 20252 phase 3 studiesPhase 3 reachedNCT07286331, NCT07286266
  5. Jun 29, 20262 phase 3 studiesNCT07684612, NCT07684599
  6. Jul 1, 2026Phase 3 study in Ovarian NeoplasmsNCT07694427 · 720 planned · Argentina, Australia, Canada and more
  7. Oct 15, 2026Primary completion moved from 2029-12-17 to 2030-07-22Date moved laterphase 3 · +7 months · NCT07286266

Ahead

  1. Sep 22, 2027Primary completion: phase 1 study in NeoplasmsNCT06431594
  2. Feb 29, 2028Primary completion: phase 3 study in Endometrial NeoplasmsNCT07286331
  3. Jul 23, 2029Primary completion: phase 3 study in Endometrial NeoplasmsNCT07684599
  4. Sep 6, 2029Primary completion: phase 3 study in Ovarian NeoplasmsNCT07694427

TargetBeta

“ADC targeting B7-H4”the company's pipeline, read by Claude · source
“B7-H4 ADC”the company's pipeline, read by Claude · source
“An antibody-drug conjugate (ADC) composed of mocertatug, a humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against B7-H4 (V-set domain-containing T-cell activation inhibitor 1; VTCN1; B7x; B7S1) ”NCIt, by rule

Other programs on VTCN1

ProgramCompanyFurthest phaseStudies
Anti-B7-H4 Antibody Drug Conjugate BG-C9074ruleBeOne Medicinesphase 32
puxitatug samrotecanAstraZenecaphase 32
Anti-B7-H4/Anti-4-1BB Bispecific Antibody ABL103ruleabl-bio-incphase 22
Anti-B7-H4/MMAE ADC LNCB74ruleligachem-biosciences-incphase 11

Studies

All 6 GlaxoSmithKline leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07694427Ovarian Neoplasms · Argentina, Australia, Canada and more3RecruitingSep 6, 2029720
NCT07684612Ovarian Neoplasms · Australia, Canada, Japan and more3RecruitingMay 21, 2030690
NCT07684599Endometrial Neoplasms · Canada, Japan, South Korea3RecruitingJul 23, 2029610
NCT07286331Endometrial Neoplasms · United States, Argentina, Australia and more3RecruitingFeb 29, 2028600
NCT07286266Ovarian Neoplasms · Australia, Canada, Japan and more3RecruitingJul 22, 2030450
NCT06431594Neoplasms · United States, Argentina, Australia and more1RecruitingSep 22, 2027675

How it is read

Names in the registry

  • “Mocertatug rezetecan”, 5 entries
  • “HS-20089”, 2 entries
  • “Mocertatug rezetecan (Mo-Rez)”, 1 entry
  • “HS-20089+Bevacizumab”, 1 entry
  • “HS-10502 + HS-20089”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.